Knott David M Jr Grows Position in Viridian Therapeutics, Inc. $VRDN

Knott David M Jr lifted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 24.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 181,000 shares of the company’s stock after purchasing an additional 36,000 shares during the quarter. Viridian Therapeutics comprises approximately 2.1% of Knott David M Jr’s holdings, making the stock its 14th largest holding. Knott David M Jr owned approximately 0.18% of Viridian Therapeutics worth $3,540,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of VRDN. ANTIPODES PARTNERS Ltd purchased a new position in Viridian Therapeutics in the fourth quarter valued at approximately $36,000. KBC Group NV acquired a new position in Viridian Therapeutics during the first quarter valued at approximately $34,000. Larson Financial Group LLC purchased a new stake in Viridian Therapeutics during the third quarter worth approximately $52,000. US Bancorp DE grew its stake in Viridian Therapeutics by 23.2% during the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after buying an additional 463 shares during the period. Finally, State of Wyoming acquired a new stake in shares of Viridian Therapeutics in the first quarter worth $93,000.

Viridian Therapeutics Stock Up 0.5%

NASDAQ VRDN opened at $19.26 on Friday. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The business has a 50 day moving average price of $17.65 and a two-hundred day moving average price of $22.48. The stock has a market cap of $1.99 billion, a PE ratio of -5.80 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. During the same quarter last year, the firm posted ($0.87) earnings per share. The business’s quarterly revenue was up 95.8% on a year-over-year basis. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -3.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Stifel Nicolaus set a $39.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, May 13th. Wedbush upped their price target on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 30th. Truist Financial increased their price target on Viridian Therapeutics from $35.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Royal Bank Of Canada raised their price objective on Viridian Therapeutics from $34.00 to $35.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Finally, The Goldman Sachs Group reissued a “buy” rating and issued a $39.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, June 30th. Thirteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $38.79.

Insiders Place Their Bets

In other news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the purchase, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This represents a 30.05% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.40% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.